decisionhealth Newsletters, Coder Pink Sheets - 2007 Issue 4 (April)
In-office ED treatment: Medicare pays only for drugs not considered self-administered
Subscribe or sign in to view the full article.
Article Overview
This article explains Medicare’s approach to in-office erectile dysfunction treatment, focusing on how carriers distinguish self-administered from physician-administered injectable drugs and why that distinction affects payment. It is relevant for urology practices, coders, and billing staff who need to understand Medicare coverage policy, carrier determinations, and training-related services for penile injection therapy. The article also references CMS guidance and discusses how frequency, route of administration, and drug packaging relate to carrier review of injectable medications.
Why This Topic Matters
Coverage for erectile dysfunction injection therapy can depend on whether a drug appears on a carrier’s self-administered list, so billing teams need to understand the policy context before submitting claims. The article helps practices avoid payment surprises for in-office training, drug supply, and related administration services.
Article Sections
-
Medicare policy background for ED injection therapy
Introduces the coverage issue and the distinction Medicare makes between self-administered and physician-administered drugs. It frames the discussion around in-office erectile dysfunction treatment.
-
Carrier guidance and factors used to determine self-administration
Summarizes the general criteria carriers use when evaluating injectable drugs for self-administration status. It also notes the role of route of administration, frequency, and CMS reporting requirements.
-
Drug categories discussed for corpora cavernosa injections
Reviews the medications referenced in the article and how they are treated in the coverage discussion. The section focuses on the practical implications for office-based treatment and patient training.
-
Clinical context and practice trends
Provides broader context about where injection therapy fits among erectile dysfunction treatment options. It also notes the article’s discussion of changing use patterns over time.
What You Will Learn
- How Medicare distinguishes between self-administered and physician-administered injectable drugs
- What factors carriers are directed to consider when reviewing injectable drug coverage
- Why in-office erectile dysfunction training and injection therapy raise billing questions
- Which general categories of drugs are discussed in relation to office-based ED treatment
- How CMS carrier list reporting relates to injectable drug coverage policy
Who Should Read This
- Medical coders
- Billing staff
- Urology practices
- Physician office administrators
- Revenue cycle teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com